Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
This study has been completed.
Sponsored by: Baxter Healthcare Corporation
Information provided by: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT00161863
  Purpose

The purpose of this study is to investigate the safety of five consecutive lots of FSME-IMMUN NEW in healthy volunteers. The main criterion for investigation is the fever rate after the first vaccination in three different age classes. The immunogenicity of 0.25 ml FSME-IMMUN NEW has been demonstrated in previous clinical studies in children; therefore, in the present study, immunogenicity was investigated in a subgroup only.


Condition Intervention Phase
Tick-Borne Encephalitis
Biological: FSME-IMMUN NEW 0.25 ml
Phase III

MedlinePlus related topics: Encephalitis
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Open-Label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Further study details as provided by Baxter Healthcare Corporation:

Study Start Date: September 2002
Estimated Study Completion Date: January 2003
  Eligibility

Ages Eligible for Study:   1 Year to 15 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

Male and female children and adolescents will be eligible for participation in this study if:

  • they are aged 1 year (from the 1st birthday) to < 16 years (to the last day before the 16th birthday);
  • they are clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial);
  • their parents/legal guardians understand the nature of the study and agree to its provisions;
  • written informed consent is available from both parents/legal guardians,
  • for Germany/Austria: additional written informed consent is available for children older than 8 years
  • they or their parents/legal guardians agree to keep a volunteer diary.

For safety reasons, female volunteers who have reached sexual maturity at study start have to meet the following additional inclusion criteria:

- negative pregnancy test at study entry;

Exclusion Criteria:

Children and adolescents will be excluded from participation in this study if they:

  • have a history of any TBE vaccination;
  • have a history of TBE infection;
  • have a history of allergic reactions to one of the components of the vaccine;
  • suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions;
  • are known to be HIV positive (a special HIV test is not required for the purpose of the study);
  • have received banked blood or immunoglobulins within one month of study entry;
  • have a history of vaccination against yellow fever and/or Japanese B-encephalitis;
  • suffer from hemorrhagic diathesis;
  • are participating simultaneously in another clinical trial;
  • if female: are pregnant or breastfeeding.

Volunteers who meet the inclusion/exclusion criteria, but have a febrile illness (body temperature > 38°C) at the scheduled time of vaccination, will not be vaccinated before their body temperature returns to normal.

Volunteers who have received any other vaccination within 4 weeks prior to visit 1 will not be vaccinated until an interval of 4 weeks has passed. In this case visit 1 will take place separately.

If volunteers have received antipyretics within 4 hours prior to the intended TBE vaccination, the vaccination should be performed at a later time.

Volunteers who have a positive TBE antibody value prior to the first vaccination will be excluded from the statistical analysis of the primary endpoint.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00161863

Locations
Austria
Grieskirchner Strasse 17
Wels, Austria, 4600
Germany
Hauptstraße 240
Kehl, Germany, 77694
Solothurner Strasse 2
Heilbronn, Germany, 74072
Marktplatz 3
Bad Saulgau, Germany, 88348
Poland
Wojewodzki Szpital Dziececy oddz. Obserwacyjno-Zakazny
Kielce, Poland, 25381
Samodzielny Publiczny ZOZ Oddzial Dzieciecy
Lubartow, Poland, 21100
Szpital Jana Pawla II Odz. Neuroinfekcji
Krakow, Poland, 31202
PANTAMED sp.z.o.o.
Olsztyn, Poland, 10-461
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
Principal Investigator: Baxter BioScience Investigator Baxter BioScience
  More Information

Study ID Numbers: 209
Study First Received: September 8, 2005
Last Updated: October 18, 2006
ClinicalTrials.gov Identifier: NCT00161863  
Health Authority: Germany: Paul-Ehrlich-Institut

Study placed in the following topic categories:
Virus Diseases
Tick-borne encephalitis
Central Nervous System Infections
Central Nervous System Diseases
Healthy
Arbovirus Infections
Brain Diseases
Tick-Borne Diseases
Encephalitis
Encephalitis, Tick-Borne

Additional relevant MeSH terms:
Encephalitis, Viral
RNA Virus Infections
Flaviviridae Infections
Flavivirus Infections
Nervous System Diseases
Central Nervous System Viral Diseases
Encephalitis, Arbovirus

ClinicalTrials.gov processed this record on January 16, 2009